3-(3,4-Difluorophenyl)-2-[[4-[2,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(3,4-Difluorophenyl)-2-[[4-[2,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]propanoic acid
• 英文别名: 3-(3,4-difluorophenyl)-2-[[4-[2,5-dimethyl-4-(1-phenylethoxycarbonylamino)pyrazol-3-yl]benzoyl]amino]propanoic acid
• 化学式: C₃₀H₂₈F₂N₄O₅
• 分子量: 562.6
• InChiKey: DLMGBRHZEUSGID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  41
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  123
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Heterocyclic compounds useful in the treatment of disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US10570103B2

  公开（公告）日：2020-02-25

  A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.

  本发明提供了一种治疗溶血磷脂酸依赖性疾病或病症的方法。 该方法包括向受试者施用治疗有效量的杂环化合物。 杂环化合物是溶血磷脂酸受体配体。 溶血磷脂酸依赖性疾病和病症包括涉及纤维化的疾病，如心脏、肾脏、肝脏和肺的纤维化以及硬皮病；炎症性疾病，如糖尿病肾病和炎症性肠病；眼部疾病，如涉及视网膜变性的疾病；神经疾病，如瘙痒和疼痛。
• HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE
  申请人：Epigen Biosciences, Inc.

  公开号：EP2988743A2

  公开（公告）日：2016-03-02
• Heterocyclic Compounds Useful In The Treatment of Disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20180297962A1

  公开（公告）日：2018-10-18

  Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.
• Heterocyclic Compounds Useful In The Treatment Of Disease
  申请人：EPIGEN BIOSCIENCES, INC.

  公开号：US20190135767A1

  公开（公告）日：2019-05-09

  A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.